Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Illumina, Caris Life Sciences, Fresenius Medical Care, More

NEW YORK – Illumina said this week that it has opened an 11,000-square-foot "Solution Center" in São Paulo to showcase its sequencing and microarray technologies and to offer training to customers and partners in Brazil and Latin America. 

Caris Life Sciences said this week that the University of Kentucky Markey Cancer Center has joined Caris' Precision Oncology Alliance, a worldwide network of cancer centers that collaborate to advance precision oncology and biomarker-driven research. The network now includes 62 cancer centers and academic institutions. Its members have early access to Caris' database and artificial intelligence platform to establish evidence-based standards for cancer profiling and molecular testing in oncology. 

Fresenius Medical Care this week announced My Reason, a campaign to increase participation in the nephrology care firm's year-old renal genomic registry. Fresenius hopes to enroll at least 100,000 patients in the registry within five years. As part of My Reason, participation will become a standard offering to patients at Fresenius dialysis centers in the US.

Premier Medical Laboratory Services said this week that it has received accreditation from the College of American Pathologists. The designation verifies that the lab meets all required standards from CLIA, the US Food and Drug Administration, and the Occupational Safety and Health Administration, the Greenville, South Carolina-based firm said. PMLS provides molecular diagnostics services for cardiovascular disease, women's health, pharmacogenomics, COVID-19, and other indications. 

Diagnostic testing firm Artemis DNA said this week that it is opening its first international location in Ho Chi Minh City, Vietnam. Starting this month, the Irvine, California-based firm will offer its genetic testing technology and portfolio, as well as a cancer screening test named Trucheck Pragma in Vietnam. The blood-based screening test was developed by cancer research company Datar Cancer Genetics for the early detection of prostate, breast, ovary, lung, stomach, colon, and pancreatic cancers. Artemis will exclusively distribute Trucheck Pragma in Vietnam. Other terms of the deal were not disclosed. 

German metabolomics firm Lifespin said this week that it has opened a US location to accelerate its access to the US clinical and research markets as it expands its business and R&D operations in the US. Based initially in Boston, the US operation will be led by Trevor Hawkins, a member of the company’s board of directors. 

ImmunoPrecise Antibodies (IPA) said this week that it has completed the acquisition of Belgian bioinformatics company BioStrand and its subsidiaries BioKey and BioClue through its wholly owned subsidiary ImmunoPrecise Netherlands. IPA paid approximately €20 million ($21.7 million) for the firms, including €3.7 million in cash and €16.3 million worth of its common stock, and may pay up to another €12 million based on the profitability of BioStrand over a seven-year period. The acquisition was first announced in March. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.